W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

They've been dubbed 'game-changers' in the world of obesity, making the seemingly impossible, possible - significant weight ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

Eli Lilly & Co. Inc.’s stock LLY rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...

Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...

Eli Lilly (LLY) stock is rising after the company said its weight-loss drug achieved better results than Wegovy ...

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative ...

Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.